Folkwein Lab
Principal investigator
Heather J Folkwein, Ph.D.
[email protected], 330-325-6750
Heather Folkwein profile
Research focus
Our lab intertwines biochemistry, structural biology, and medicinal chemistry to understand how the protein complexes that control gene expression and cell growth fail in neurodegenerative diseases, as well as a rare genetic disorder known as Tuberous Sclerosis Complex, and to use those structures as a foundation for new therapies.
A major focus is TDP-43, an RNA and DNA binding protein found in the pathology of nearly every major neurodegenerative disease, from ALS and frontotemporal dementia to Alzheimer’s and Parkinson’s. Our central hypothesis is that TDP-43 binds the chromatin remodelers and sequesters them from the nucleosome, shutting down the stress-response genes that neurons rely on to survive. Combining biochemical reconstitution with cryo-EM, we aim to solve the structure of this inhibitory complex and determine whether TDP-43 sequesters the remodeler or inhibits it directly. That interface would be a real therapeutic target.
In parallel, we study the TSC1/TSC2 complex, the central regulator of mTOR signaling through Rheb. Loss-of-function mutations cause Tuberous Sclerosis, a disorder with no cure in which non-cancerous tumors arise throughout the body. By improving the resolution of the complex, mapping patient mutations onto its structure to see how they disrupt assembly and function then testing these variants in cell-based models, we can gain further understanding into this disorder. This structural insight will guide the design of improved therapies.
Across both projects, our conviction is the same: once you can see how a molecular machine is built, you can finally understand why it breaks, and how to ultimately repair it.
Current work
Our lab is just getting started, and our first effort builds toward the TDP-43 question at the center of our research. We are currently generating the constructs and purifying the components needed to reconstitute the TDP-43–remodeler complex, developing the biochemical assays to measure how TDP-43 alters remodeler activity, and establishing the cryo-EM pipeline that will let us solve its structure. The immediate goal is to distinguish whether TDP-43 sequesters the remodeler from the nucleosome or inhibits it directly, since each mechanism points toward a different therapeutic strategy. We are actively recruiting students and postdocs who want to help build this work from the ground up.
Select publications
- Nodelman IM, Folkwein HJ, Glime WS, Armache JP, Bowman GD. A competitive regulatory mechanism of the Chd1 remodeler is integral to distorting nucleosomal DNA. Nat Struct Mol Biol. 2025 Aug;32(8):1445-1455. PubMed Central PMCID: PMC12879502
- Chakraborty U, Saccone EC, Cruz-Becerra G, Khan LF, Arslanovic N, Aguilar R, Gloor SL, Hunt SR, Folkwein HJ, Husby NL, Maier KE, Marunde MR, Schomburg NK, Vaidya A, Cowles MW, Venters BJ, Kassavetis G, Sun ZW, Kadonaga JT, Armache JP, Keogh MC, Tyler JK. Different modes of engagement with the nucleosome acidic patch yield distinct functional outcomes. bioRxiv. 2026 Jan 14; PubMed Central PMCID: PMC12871379.
- Ortiz-Rodríguez LA, Fang YG, Niogret G, Hadidi K, Hoehn SJ, Folkwein HJ, Jockusch S, Tor Y, Cui G, Levi L, Crespo-Hernández CE. Thieno[3,4-d]pyrimidin-4(3H)-thione: an effective, oxygenation independent, heavy-atom-free photosensitizer for cancer cells. Chem Sci. 2023 Aug 23;14(33):8831-8841. PubMed Central PMCID: PMC10445467.
- Guo J, Linetsky M, Yu AO, Zhang L, Howell SJ, Folkwein HJ, Wang H, Salomon RG. 4-Hydroxy-7-oxo-5-heptenoic Acid Lactone Induces Angiogenesis through Several Different Molecular Pathways. Chem Res Toxicol. 2016 Dec 19;29(12):2125-2135. PubMed Central PMCID: PMC5349710.
Select collaborators
- Jean-Paul Armache, Penn State University